- Home
- CYH vs PLRX Comparison
CYH vs PLRX Comparison
Compare CYH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- PLRX
- Stock Information
- Founded
- CYH 1985
- PLRX 2015
- Country
- CYH United States
- PLRX United States
- Employees
- CYH N/A
- PLRX N/A
- Industry
- CYH Hospital/Nursing Management
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- PLRX Health Care
- Exchange
- CYH Nasdaq
- PLRX Nasdaq
- Market Cap
- CYH 410.5M
- PLRX 93.3M
- IPO Year
- CYH 1991
- PLRX 2020
- Fundamental
- Price
- CYH $3.77
- PLRX $1.61
- Analyst Decision
- CYH Hold
- PLRX Hold
- Analyst Count
- CYH 8
- PLRX 11
- Target Price
- CYH $3.73
- PLRX $3.93
- AVG Volume (30 Days)
- CYH 2.8M
- PLRX 1.0M
- Earning Date
- CYH 10-23-2025
- PLRX 11-07-2025
- Dividend Yield
- CYH N/A
- PLRX N/A
- EPS Growth
- CYH N/A
- PLRX N/A
- EPS
- CYH 2.47
- PLRX N/A
- Revenue
- CYH $12,644,000,000.00
- PLRX N/A
- Revenue This Year
- CYH N/A
- PLRX N/A
- Revenue Next Year
- CYH $2.46
- PLRX N/A
- P/E Ratio
- CYH $1.53
- PLRX N/A
- Revenue Growth
- CYH 0.74
- PLRX N/A
- 52 Week Low
- CYH $2.24
- PLRX $1.10
- 52 Week High
- CYH $4.64
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- CYH 58.02
- PLRX 47.78
- Support Level
- CYH $3.67
- PLRX $1.61
- Resistance Level
- CYH $4.43
- PLRX $1.95
- Average True Range (ATR)
- CYH 0.25
- PLRX 0.13
- MACD
- CYH 0.03
- PLRX -0.01
- Stochastic Oscillator
- CYH 53.73
- PLRX 20.00
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.